Distribution of molecular breast cancer subtypes among Tunisian women and correlation with histopathological parameters: A study of 194 patients

Pathology Research and Practice

Volumn 206, Issue 11, 2010, Pages 772-775

  Abdelkrim, Soumaya Ben ^a   Trabelsi, Amel ^a   Missaoui, Nabiha ^a   Beizig, Nadia ^a   Bdioui, Ahlem ^a   Anjorin, Affissath ^a   Jomaa, Wafa ^a   Mokni, Moncef ^a  

^a FARHAT HACHED HOSPITAL   (Tunisia)

Author keywords

Breast cancer; Molecular subtype; Prognosis; Tunisia

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE METASTASIS; MOLECULAR DYNAMICS; PHENOTYPE; PROGNOSIS; PROTEIN FUNCTION; TUMOR VOLUME; TUNISIA;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL; TUNISIA; YOUNG ADULT;

EID: 77958456891     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.07.012     Document Type: Article

References (24)

1. Hsairi M., Fakhfakh R., Ben Abdallah M., Jlidi R., Sellami A., Zheni S., et al. Assessment of cancer incidence in Tunisia 1993-1997. Tunis Med. 2002, 80:57-64.
2. Ben Hamida A., Labidi I.S., Mrad K., Charafe-Jauffret E., Ben Arab S., Esterni B., et al. Markers of subtypes in inflammatory breast cancer studied by immunohistochemistry: prominent expression of P-cadherin. BMC Cancer 2008, 8:28.
3. Zhang H.M., Zhang B.N., Xuan L.X., Zhao P. Clinical characteristics and survival in the operable breast cancer patients with different molecular subtype. Zhonghua Zhong Liu Za Zhi 2009, 31:447-451.
4. Ihemelandu C.U., Leffall L.D., Dewitty R.L., Naab T.J., Mezghebe H.M., Makambi K.H., et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J. Surg. Res. 2007, 143:109-118.
5. Raica M., Jung I., Cîmpean A.M., Suciu C., Mureşan A.M. From conventional pathologic diagnosis to the molecular classification of breast carcinoma: are we ready for the change?. Rom. J. Morphol. Embryol. 2009, 50:5-13.
6. Robbins P., Pinder S., de Klerk N., Dawkins H., Harvey J., Sterrett G., et al. Histological grading of breast carcinomas: a study of interobserver agreement. Hum. Pathol. 1995, 26:873-879.
7. Wiechmann L., Sampson M., Stempel M., Jacks L.M., Patil S.M., King T., et al. Presenting features of breast cancer differ by molecular subtype. Ann. Surg. Oncol. 2009, 16:2705-2710.
8. Muñoz M., Fernández-Aceñero M.J., Martín S., Schneider J. Prognostic significance of molecular classification of breast invasive ductal carcinoma. Arch. Gynecol. Obstet. 2009, 280:43-48.
9. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10869-10874.
10. Brenton J.D., Carey L.A., Ahmed A.A., Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J. Clin. Oncol. 2005, 23:7350-7360.
11. Fabian C.J., Kimler B.F., Elledge R.M., Grizzle W.E., Beenken S.W., Ward J.H. Models for early chemoprevention trials in breast cancer. Hematol. Oncol. Clin. North Am. 1998, 12:993-1017.
12. Nguyen P.L., Taghian A.G., Katz M.S., Niemierko A., Abi Raad R.F., Boon W.L., et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J. Clin. Oncol. 2008, 26:2373-2378.
13. Del Casar J.M., Martín A., García C., Corte M.D., Alvarez A., Junquera S., et al. Characterization of breast cancer subtypes by quantitative assessment of biological parameters: relationship with clinicopathological characteristics, biological features and prognosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2008, 141:147-152.
14. Spitale A., Mazzola P., Soldini D., Mazzucchelli L., Bordoni A. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann. Oncol. 2009, 20:628-635.
15. Huo D., Ikpatt F., Khramtsov A., Dangou J.M., Nanda R., Dignam J., et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J. Clin. Oncol. 2009, 27:4515-4521.
16. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:8418-8423.
17. Sotiriou C., Neo S.Y., McShane L.M., Korn E.L., Long P.M., Jazaeri A., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:10393-10398.
18. Zhao J., Liu H., Wang M., Gu L., Guo X., Gu F., et al. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J. Surg. Oncol. 2009, 100:89-94.
19. Tian X.S., Cong M.H., Zhou W.H., Zhu J., Chen Y.Z., Liu Q. Clinicopathologic and prognostic characteristics of triple-negative breast cancer. Onkologie 2008, 31:610-614.
20. Miron L., Marinca A., Marinca M., Miron I. Triple-negative breast cancer-towards a new entity. Rev. Med. Chir. Soc. Med. Nat. Iasi 2008, 112:51-58.
21. Hicks D.G., Short S.M., Prescott N.L., Tarr S.M., Coleman K.A., Yoder B.J., et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am. J. Surg. Pathol. 2006, 30:1097-1104.
22. Crabb S.J., Cheang M.C., Leung S., Immonen T., Nielsen T.O., Huntsman D.D., et al. Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin. Breast Cancer 2008, 8:249-256.
23. Anders C., Carey L.A. Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 2008, 22:1233-1239.
24. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.